Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23924660 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)
Condition: Hepatitis C, Chronic
Interventions: Drug: Boceprevir;   Drug: Peginterferon alfa-2b (PEG2b);   Drug: Ribavirin (RBV);   Drug: Erythropoietin

Indicates status has not been verified in more than two years